DEF 14A

DEF 14A 1 eypt_def_14a_04-28-2023.htm DEF 14A DEF 14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

EyePoint Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11




480 Pleasant Street, Suite C400 Watertown, MA 02472 United States

April 28, 2023 To Our Stockholders, 2022 was another successful year as we kept our Eye on Innovation™ and made meaningful progress executing our strategy to bring sight-saving therapeutics to patients living with serious eye disorders.		We are keenly focused on delivering first-in-class therapeutics and technologies to provide a brighter future for those at risk of losing their sight.

EyePoint has a world-class sustained delivery platform for ocular treatments with our erodible Durasert E™ technology, and we are keenly focused on delivering first-in-class therapeutics and technologies to provide a brighter future for those at risk of losing their sight. In 2022, we advanced our lead pipeline program, EYP-1901, into separate Phase 2 clinical trials in wet age-related macular degeneration (AMD) and non-proliferative diabetic retinopathy (NPDR) following positive Phase 1 DAVIO results. We are incredibly excited by EYP-1901’s potential as a differentiated therapeutic for the sustained delivery of vorolanib, a tyrosine kinase inhibitor, over a period of 6-9 months. In the Phase 1 DAVIO trial, a majority of patients did not require any supplemental therapy for up to six months after a single EYP-1901 treatment. Additionally, EYP-1901 brings a new mechanism of action for treating retinal disease by blocking multiple VEGF receptors. We also presented compelling preclinical data at ARVO 2023 demonstrating potential neuroprotection by vorolanib using a validated mouse model. These data highlight the differentiated profile of vorolanib for treating retinal diseases compared to existing anti-VEGF large molecule therapies. On March 27, 2023, we announced the completion of enrollment for the Phase 2 DAVIO 2 clinical trial of EYP-1901 in wet AMD, and look forward to reporting topline results in the fourth quarter 2023. We also remain on track to complete enrollment of our Phase 2 PAVIA trial of EYP-1901 in NPDR in the fourth quarter of 2023. With millions of people in need of new treatments for these serious eye diseases, we look forward to providing updates on the DAVIO 2 and PAVIA trials in coming quarters.		In addition, we achieved exceptional sales results in 2022 with $28.3 million of net product revenue for YUTIQ®, our treatment for posterior segment uveitis with a constant and stable release of fluocinolone acetonide using Durasert® to help prevent uveitis flares for up to three years. This revenue growth represents a 67% increase compared with 2021 and was driven by strong customer demand from retinal specialists. Looking ahead, we are actively engaged in expanding our sustained ocular delivery pipeline to drive future company growth and long-term value for shareholders. We look forward to initiating a third Phase 2 clinical trial evaluating EYP-1901 in diabetic macular edema (DME) early next year, and continue to evaluate a variety of molecules for potential use in our Durasert technology, which can be tailored to each drug and disease indication. In February 2023, we announced an exciting research collaboration with Rallybio to evaluate their C5 complement inhibitor using our Durasert technology to develop a potential sustained delivery treatment option for geographic atrophy. Stay tuned for additional updates on this collaboration and our other planned pipeline expansion efforts. To support our pipeline progress and meet the long-term needs of our patients, employees, and shareholders, we completed a number of significant corporate milestones in 2022 and recent months. This includes entering into a lease agreement for the construction of a commercial manufacturing facility to support global product supply of EYP-1901 and YUTIQ, giving us a high-level of control over our supply chain and an important point of value differentiation for YUTIQ, and eventually, EYP-1901.


When it comes to matters of sight, innovation is our vision.

We strengthened our leadership with the promotion of Jay S. Duker, M.D., to the additional role of President. Dr. Duker has made invaluable contributions to EyePoint since he joined the Board in 2016, and in this expanded role, he will continue his duties as COO, while also overseeing regulatory affairs. We look forward to continuing to benefit from his strong leadership and his deep clinical expertise as a practicing retinal surgeon. We also enhanced our Board with the additions of Tony Adamis, M.D. and Karen Zaderej. Both Dr. Adamis and Ms. Zaderej bring decades of unique research and development experience from the biopharmaceutical industry, and each have already made integral contributions to EyePoint’s Board, as we strive to represent all shareholder perspectives and voices. I am grateful for the dedicated and talented team at EyePoint Pharmaceuticals, who continue to drive our progress and are responsible for our company’s clinical, operational, and financial success to date. We’ve made tremendous progress in the last year and are excited and motivated to advance the future of sustained ocular drug delivery to benefit the millions of patients at risk of serious vision loss. On behalf of the entire EyePoint team, I thank you, our committed stockholders, for your continued support as together we work towards providing better solutions for patients with serious eye diseases – because when it comes to matters of sight, innovation is our vision.		Sincerely, Nancy Lurker, Chief Executive Officer Goran Ando, M.D., Chairman of the Board

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this proxy deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration and non-proliferative diabetic retinopathy; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; extent to which our business, the medical community and the global economy will continue to be materially and adversely impacted by the effects of the COVID-19 pandemic, or by other pandemics, epidemics or outbreaks; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of our commercialized products, YUTIQ® and DEXYCU®; the loss of pass-through reimbursement status for DEXYCU as of January 1, 2023; market acceptance of our products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the potential impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy, and the impact of general business and economic conditions; instability in macroeconomic factors including changes in inflation, interest rates and the labor market; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

NOTICE OF 2023 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD JUNE 20, 2023

Dear Stockholders:

NOTICE IS HEREBY GIVEN that the 2023 Annual Meeting of Stockholders (Annual Meeting) of EyePoint Pharmaceuticals, Inc. (the Company) will be held on June 20, 2023 at 9:00 a.m., Eastern Time. This year’s Annual Meeting will be a virtual meeting via live webcast on the Internet. You will not be able to attend

SEC Form DEF 14A filed by EyePoint Pharmaceuticals Inc.